Patents by Inventor Mitsuhito Shibasaki
Mitsuhito Shibasaki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11261155Abstract: Provided is a compound having a formyl peptide receptor like 1 (FPRL1) agonist effect. The present invention relates to a compound represented by the general formula (I) or a pharmacologically acceptable salt thereof. The present invention also relates to a pharmaceutical composition containing the compound represented by the general formula (I) or a pharmacologically acceptable salt thereof.Type: GrantFiled: May 21, 2020Date of Patent: March 1, 2022Assignee: Kyorin Pharmaceutical Co., Ltd.Inventors: Hiroyasu Takahashi, Yoshifumi Saito, Kosuke Tsuda, Mitsuhito Shibasaki, Kohei Ohata
-
Publication number: 20210107869Abstract: Provided is a compound having a formyl peptide receptor like 1 (FPRL1) agonist effect. The present invention relates to a compound represented by the general formula (I) or a pharmacologically acceptable salt thereof. The present invention also relates to a pharmaceutical composition containing the compound represented by the general formula (I) or a pharmacologically acceptable salt thereof.Type: ApplicationFiled: May 21, 2020Publication date: April 15, 2021Inventors: Hiroyasu Takahashi, Yoshifumi Saito, Kosuke Tsuda, Mitsuhito Shibasaki, Kohei Ohata
-
Patent number: 10858314Abstract: The present invention provides a urea compound or a pharmacologically acceptable salt thereof that has a formyl peptide receptor like 1 (hereinafter may be abbreviated as FPRL1) agonist effect, a pharmaceutical composition containing the urea compound or the pharmacologically acceptable salt thereof and a pharmaceutical use thereof. It has been found that a urea derivative represented by the general formula (I) below or a pharmacologically acceptable salt thereof has a superior FPRL1 agonist effect. Compound (I) or a pharmacologically acceptable salt thereof is highly useful for treatment, prevention, or suppression of inflammatory diseases, chronic airway diseases, cancers, septicemia, allergic symptoms, HIV retrovirus infection, circulatory disorders, neuroinflammation, nervous disorders, pains, prion diseases, amyloidosis, immune disorders and the like.Type: GrantFiled: May 26, 2016Date of Patent: December 8, 2020Assignee: Kyorin Pharmaceutical Co., Ltd.Inventors: Hiroyasu Takahashi, Hiroyuki Watanabe, Kiyoshi Fujii, Mitsuhito Shibasaki, Mikako Kawashima, Megumi Kamiya, Kohei Ohata
-
Patent number: 10696630Abstract: Provided is a compound having a formyl peptide receptor like 1 (FPRL1) agonist effect. The present invention relates to a compound represented by the general formula (I) or a pharmacologically acceptable salt thereof. The present invention also relates to a pharmaceutical composition containing the compound represented by the general formula (I) or a pharmacologically acceptable salt thereof.Type: GrantFiled: September 24, 2019Date of Patent: June 30, 2020Assignee: Kyorin Pharmaceuticals Co., Ltd.Inventors: Hiroyasu Takahashi, Yoshifumi Saito, Kosuke Tsuda, Mitsuhito Shibasaki, Kohei Ohata
-
Publication number: 20200010415Abstract: Provided is a compound having a formyl peptide receptor like 1 (FPRL1) agonist effect. The present invention relates to a compound represented by the general formula (I) or a pharmacologically acceptable salt thereof. The present invention also relates to a pharmaceutical composition containing the compound represented by the general formula (I) or a pharmacologically acceptable salt thereof.Type: ApplicationFiled: September 24, 2019Publication date: January 9, 2020Inventors: Hiroyasu Takahashi, Yoshifumi Saito, Kosuke Tsuda, Mitsuhito Shibasaki, Kohei Ohata
-
Patent number: 10525058Abstract: The present invention provides a urea derivative or a pharmacologically acceptable salt thereof that has a formyl peptide receptor like 1 (hereinafter may be abbreviated as FPRL1) agonist effect, a pharmaceutical composition containing the urea derivative or the pharmacologically acceptable salt thereof, and a pharmaceutical use thereof. It has been found that a urea derivative represented by the general formula (I) below or a pharmacologically acceptable salt thereof has a superior FPRL1 agonist effect. Compound (I) or a pharmacologically acceptable salt thereof is highly useful for treatment, prevention, or suppression of inflammatory diseases, chronic airway diseases, cancers, septicemia, allergic symptoms, HIV retrovirus infection, circulatory disorders, neuroinflammation, nervous disorders, pains, prion diseases, amyloidosis, immune disorders and the like.Type: GrantFiled: May 26, 2016Date of Patent: January 7, 2020Assignee: KYORIN PHARMACEUTICAL CO., LTDInventors: Kiyoshi Fujii, Kentaro Umei, Hiroyasu Takahashi, Mitsuhito Shibasaki, Kohei Ohata
-
Patent number: 10464891Abstract: Provided is a compound having a formyl peptide receptor like 1 (FPRL1) agonist effect. The present invention relates to a compound represented by the general formula (I) or a pharmacologically acceptable salt thereof. The present invention also relates to a pharmaceutical composition containing the compound represented by the general formula (I) or a pharmacologically acceptable salt thereof.Type: GrantFiled: February 7, 2019Date of Patent: November 5, 2019Assignee: Kyorin Pharmaceuticals Co., Ltd.Inventors: Hiroyasu Takahashi, Yoshifumi Saito, Kosuke Tsuda, Mitsuhito Shibasaki, Kohei Ohata
-
Publication number: 20190161445Abstract: Provided is a compound having a formyl peptide receptor like 1 (FPRL1) agonist effect. The present invention relates to a compound represented by the general formula (I) or a pharmacologically acceptable salt thereof. The present invention also relates to a pharmaceutical composition containing the compound represented by the general formula (I) or a pharmacologically acceptable salt thereof.Type: ApplicationFiled: February 7, 2019Publication date: May 30, 2019Inventors: Hiroyasu Takahashi, Yoshifumi Saito, Kosuke Tsuda, Mitsuhito Shibasaki, Kohei Ohata
-
Patent number: 10252992Abstract: Provided is a compound having a formyl peptide receptor like 1 (FPRL1) agonist effect. The present invention relates to a compound represented by the general formula (I) or a pharmacologically acceptable salt thereof. The present invention also relates to a pharmaceutical composition containing the compound represented by the general formula (I) or a pharmacologically acceptable salt thereof.Type: GrantFiled: June 18, 2018Date of Patent: April 9, 2019Assignee: Kyorin Pharmaceutical Co., Ltd.Inventors: Hiroyasu Takahashi, Yoshifumi Saito, Kosuke Tsuda, Mitsuhito Shibasaki, Kohei Ohata
-
Publication number: 20180290974Abstract: Provided is a compound having a formyl peptide receptor like 1 (FPRL1) agonist effect. The present invention relates to a compound represented by the general formula (I) or a pharmacologically acceptable salt thereof. The present invention also relates to a pharmaceutical composition containing the compound represented by the general formula (I) or a pharmacologically acceptable salt thereof.Type: ApplicationFiled: June 18, 2018Publication date: October 11, 2018Inventors: Hiroyasu Takahashi, Yoshifumi Saito, Kosuke Tsuda, Mitsuhito Shibasaki, Kohei Ohata
-
Publication number: 20180208552Abstract: The present invention provides a urea compound or a pharmacologically acceptable salt thereof that has a formyl peptide receptor like 1 (hereinafter may be abbreviated as FPRL1) agonist effect, a pharmaceutical composition containing the urea compound or the pharmacologically acceptable salt thereof, and a pharmaceutical use thereof. It has been found that a urea derivative represented by the general formula (I) below or a pharmacologically acceptable salt thereof has a superior FPRL1 agonist effect. Compound (I) or a pharmacologically acceptable salt thereof is highly useful for treatment, prevention, or suppression of inflammatory diseases, chronic airway diseases, cancers, septicemia, allergic symptoms, HIV retrovirus infection, circulatory disorders, neuroinflammation, nervous disorders, pains, prion diseases, amyloidosis, immune disorders and the like.Type: ApplicationFiled: May 26, 2016Publication date: July 26, 2018Applicant: KYORIN PHARMACEUTICAL CO., LTD.Inventors: Hiroyasu TAKAHASHI, Hiroyuki WATANABE, Kiyoshi FUJII, Mitsuhito SHIBASAKI, Mikako KAWASHIMA, Megumi KAMIYA, Kohei OHATA
-
Publication number: 20180207153Abstract: The present invention provides a urea derivative or a pharmacologically acceptable salt thereof that has a formyl peptide receptor like 1 (hereinafter may be abbreviated as FPRL1) agonist effect, a pharmaceutical composition containing the urea derivative or the pharmacologically acceptable salt thereof, and a pharmaceutical use thereof. It has been found that a urea derivative N represented by the general formula (I) below or a pharmacologically acceptable salt thereof has a superior FPRL1 agonist effect. Compound (I) or a pharmacologically acceptable salt thereof is highly useful for treatment, prevention, or suppression of inflammatory diseases, chronic airway diseases, cancers, septicemia, allergic symptoms, HIV retrovirus infection, circulatory disorders, neuroinflammation, nervous disorders, pains, prion diseases, amyloidosis, immune disorders and the like.Type: ApplicationFiled: May 26, 2016Publication date: July 26, 2018Applicant: KYORIN PHARMACEUTICAL CO., LTD.Inventors: Kiyoshi FUJII, Kentaro UMEI, Hiroyasu TAKAHASHI, Mitsuhito SHIBASAKI, Kohei OHATA
-
Patent number: 10029983Abstract: Provided is a compound having a formyl peptide receptor like 1 (FPRL1) agonist effect. The present invention relates to a compound represented by the general formula (I) or a pharmacologically acceptable salt thereof. The present invention also relates to a pharmaceutical composition containing the compound represented by the general formula (I) or a pharmacologically acceptable salt thereof.Type: GrantFiled: October 3, 2017Date of Patent: July 24, 2018Assignee: Kyorin Pharmaceutical Co., Ltd.Inventors: Hiroyasu Takahashi, Yoshifumi Saito, Kosuke Tsuda, Mitsuhito Shibasaki, Kohei Ohata
-
Publication number: 20180044290Abstract: Provided is a compound having a formyl peptide receptor like 1 (FPRL1) agonist effect. The present invention relates to a compound represented by the general formula (I) or a pharmacologically acceptable salt thereof. The present invention also relates to a pharmaceutical composition containing the compound represented by the general formula (I) or a pharmacologically acceptable salt thereof.Type: ApplicationFiled: October 3, 2017Publication date: February 15, 2018Inventors: Hiroyasu Takahashi, Yoshifumi Saito, Kosuke Tsuda, Mitsuhito Shibasaki, Kohei Ohata
-
Patent number: 9822069Abstract: Provided is a compound having a formyl peptide receptor like 1 (FPRL1) agonist effect. The present invention relates to a compound represented by the general formula (I) or a pharmacologically acceptable salt thereof. The present invention also relates to a pharmaceutical composition containing the compound represented by the general formula (I) or a pharmacologically acceptable salt thereof.Type: GrantFiled: November 27, 2014Date of Patent: November 21, 2017Assignee: Kyorin Pharmaceutical Co., Ltd.Inventors: Hiroyasu Takahashi, Yoshifumi Saito, Kosuke Tsuda, Mitsuhito Shibasaki, Kohei Ohata
-
Publication number: 20170066718Abstract: Provided is a compound having a formyl peptide receptor like 1 (FPRL1) agonist effect. The present invention relates to a compound represented by the general formula (I) or a pharmacologically acceptable salt thereof. The present invention also relates to a pharmaceutical composition containing the compound represented by the general formula (I) or a pharmacologically acceptable salt thereof.Type: ApplicationFiled: November 27, 2014Publication date: March 9, 2017Inventors: Hiroyasu Takahashi, Yoshifumi Saito, Kosuke Tsuda, Mitsuhito Shibasaki, Kohei Ohata